ABL Signs Know-How License and Transfer Agreement for Siemens’ Fast Track Diagnostics PCR Portfolio

Advanced Biological Laboratories (ABL, Luxembourg Ville, Luxembourg) has signed a licensing and transfer agreement with Siemens Healthineers (Forchheim, Germany) for the know-how and IP rights from Fast Track Diagnostics Luxembourg (FTD).

FTD was engaged in developing, manufacturing, and selling in-vitro diagnostic and research using only molecular testing products. As the owner of FTD, Siemens has licensed and transferred the know-how and IP rights to ABL and its affiliates (ABL Group) related to the design and manufacturing of certain former FTD products. Based on this Know-How License and Transfer Agreement (Agreement), the ABL group intends to manufacture and commercialize its testing products equivalent to the former FTD products. The licensed know-how is related to real-time Polymerase Chain Reaction (PCR) tests, allowing for both singleplex and syndromic testing, to target conditions such as respiratory infections, gastroenteritis, meningitis, hepatitis, infections of the immunosuppressed, tropical diseases, sexually transmitted diseases, and early childhood diseases, and detect over 100 viruses, bacteria, parasites, and fungi.

Unlike a clinical examination alone, it can distinguish between viral, bacterial, or other infections in one test. By integrating new PCR tests based on FTD know-how and IP rights to its molecular diagnostics portfolio, ABL Group is further investing in precision medicine and better patient experience through solutions that eliminate the need for repeat diagnostic testing, reducing time and improving patient outcomes. The Agreement expands the ABL Group molecular diagnostics portfolio with a potential of up to 38 products to be manufactured within the ABL UltraGene family. ABL intends to develop a combined strategy of reflex testing from these new products and the DeepChek products for genotyping sequencing. This will further expand ABL’s footprint in infectious diseases by being a global supplier of standalone software, detection tests, and genotyping by sequencing tests. The expanded ABL portfolio, tests, and syndromic panels, can help transform care delivery for its customers with a comprehensive solution for molecular testing of infectious diseases. In addition, ABL's platform-agnostic menu allows ABL Group to effectively serve a broader customer base.

"By integrating the high-quality of the know-how developed by Fast Track Diagnostics into our own cutting-edge molecular diagnostics portfolio, ABL continues to strengthen and expand its presence in the field of molecular testing and precision medicine," said Dr. Chalom B. Sayada, CEO and Founder, Advanced Biological Laboratories. "It means great things for all of our customers globally and delivers better outcomes for their patients."

"We are excited to manufacture our new ABL UltraGene products using FTD’s know-how and IP rights and to integrate them into our compliance plan to the European regulation for in-vitro diagnostics medical devices (2017/746, IVDR)," added Ronan Boulmé, GRC Director for the ABL Group.